On September 9, 2025, Prathyusha Duraibabu resigned as Chief Financial Officer of Sangamo Therapeutics, effective October 1, 2025, to pursue another opportunity, with no disagreements reported regarding company operations. Her efforts have significantly contributed to the company’s strategic collaborations and future positioning.